关键词: 淋巴瘤, CD20, 免疫治疗

Abstract: BACKGROUND ＆ AIM: By transfecting the CD20_scFv_IgGFc recombinant pLNCX plasmid into T lymphocytes and employing the anchored T lymphocytes to attack the Raji lymphoma cells in vitro, to explore the capability of the anchored T lymphocytes in inducing apoptosis of Raji cells. MATERIALS AND METHODS: Recombinant plasmid was transfected into retrovirus_packed PA317 cell lines with lipofectamine reagent, and then the growth of the trancfectants were selected in a medium supplemented with G418(600 μg/ml) for 3 weeks. Raji cells were attacked by T lymphocytes with and without transfected PA317 supernatant. The AnnexinⅤ and Bcl_2 positive rates in Raji cells at different times were monitored by flow cytometry. RESULTS: The expressions of Annexin V and Bcl_2 in CD20＋ Raji cells were obviously different to the control group within 24 hours. CONCLUSION: Anti_CD20_scFv_IgGFc modified T cells could provoke Raji cells apoptosis within several hours. AnnexinⅤ may initiate Raji early apoptosis, and meanwhile genetically modified T cells could inhibit Bcl_2 expression of Raji cells to its speed up its apoptosis.

Key words: lymphoma, CD20, immunotherapy